

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**Segment wise Revenue, Results and Capital Employed,
under Clause 41 of the Listing Agreement**

(Rs. lakhs)

Unaudited			Unaudited		Audited
3 months ended 30.09.2006	3 months ended 30.09.2005		9 months ended 30.09.2006	9 months ended 30.09.2005	Year ended 31.12.2005
		1. Segment Revenue:			
36914	36082	a) Pharmaceuticals	110922	101481	128635
4006	6860	b) Other Businesses	15080	16663	23066
40920	42942	Total Segment Revenue	126002	118144	151701
-	-	Less: Inter Segment Revenue	-	-	-
40920	42942	Net Sales / Income from Operations	126002	118144	151701
		2. Segment Results (Profit before Interest and Tax):			
13219	12538	a) Pharmaceuticals	39868	35298	41630
954	1859	b) Other Businesses	3004	3312	5199
14173	14397	Total Segment Results	42872	38610	46829
		Add/(Less):			
926	555	(i) Interest Income (net)	2419	1615	2345
(143)	(284)	(ii) Unallocable Income Net of Unallocable Expenditure	(419)	(716)	(1383)
14956	14668	Total Profit Before Tax and Exceptional Items	44872	39509	47791
		3. Capital Employed (Segment Assets less Segment Liabilities):			
16725	14463	a) Pharmaceuticals	16725	14463	11975
5812	7818	b) Other Businesses	5812	7818	7563
22537	22281	Total Capital Employed in Segments	22537	22281	19538

Notes:

- 1 Refer notes 2, 3 and 6 of the aforesaid unaudited financial results for the quarter ended 30th September, 2006.
- 2 (i) The Company is organised into two main business segments, namely:
 - Pharmaceuticals - comprising of bulk drugs and formulations
 - Others - primarily comprising of veterinary formulations, feed supplements, fine chemicals, diagnostics, laboratory equipment and exports mainly relating to pharmaceuticals.

Segments have been identified and reported taking into account, the nature of products and services, the differing risks and returns, the organisation structure, and the internal financial reporting systems.

(ii) Segment Revenue in each of the above domestic business segments primarily includes sales (net of excise duty), processing charges, consignment sales commission, clinical research and data management and export incentives in the respective segments.

(iii) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.